LACTOFERIN IN THE PROBLEM OF ANTI-INFECTIOUS PROTECTION OF BABIES IN THEIR FIRST YEAR OF LIVING

The author  summarizes  the  results  of research  of the  antibacterial,  antiviral  and  antifungal  properties  of multifunctional  human protein  — lactoferrin,  in order  to determine  the prospects  for its use in the prevention  and  treatment  of infectious  diseases  of children in their first year of life. The mechanisms of anti-infectious effect of this protein with breastfed children have been described. Basic differences between human lactoferrin and cattle lactoferrin have been shown. Biotechnology of obtaining recombinant human lactoferrin from the milk of genetically engineered dairy animals (goat-producers) has been described. According to the studies, both by physical and chemical parameters and biological activity, human lactoferrin, obtained from milk-producing  goats, corresponds to its natural counterpart.

1. amr-review [Internet]. The review on antimicrobial resistance. O'Neill J, reviewer. Tackling drug-resistant infections globally: final report and recommendations. 2016 [cited 2016 Nov 9]. Available from: https://amr-review.org.

2. Практическое руководство по антиинфекционной химиотерапии / Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. — М.: Боргес; 2002. — 379 с. [Prakticheskoe rukovodstvo po antiinfektsionnoi khimioterapii. Ed by Strachunskii L.S., Belousov Yu.B., Kozlov S.N. Moscow: Borges; 2002. 379 p. (In Russ).]

3. Warren S, Garcia M, Hankins C. Impact of neonatal early onset sepsis calculator on antibiotic use within two tertiary healthcare centers. J Perinatol. 2016. doi: 10.1038/jp.2016.236.

4. Kristof K, Szabo D, Marsh JW, et al. Extended-spectrum beta-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology. Eur J Clin Microbiol Infect Dis. 2007;26(8):563-570. doi: 10.1007/s10096-007-0338-9.

5. Farnaud S, Evans RW. Lactoferrin a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40(7):395-405. doi: 10.1016/s0161-5890(03)00152-4.

6. Manzoni P Tarnow-Mordi W, Franco C, et al. Clinical use of lactoferrin in preterm neonates: an update. Minerva Pediatr. 2010;62(3 Suppl 1):101-104.

7. Aumuller G, Riva A. Morphology and functions of the human seminal vesicle. Andrologia. 1992;24(4):183-196. doi: 10.1111/j.1439-0272.1992.tb02636.x.

8. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci. 2005;62(22):2540-2548. doi: 10.1007/s00018-005-5369-8.

9. Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS. 1999; 107(7-12):971-981. doi: 10.1111/j.1699-0463.1999.tb01499.x.

10. Somm E, Larvaron P van de Looij Y, et al. Protective effects of maternal nutritional supplementation with lactoferrin on growth and brain metabolism. Pediatr Res. 2014;75(1-1):51-61. doi: 10.1038/pr.2013.199.

11. Zhang Y, Wang X, Qiu Y, et al. Effect of indomethacin and lactoferrin on human tenocyte proliferation and collagen formation in vitro. Biochem Biophys Res Commun. 2014;454(2):301-307. doi: 10.1016/j.bbrc.2014.10.061.

12. Pietrantoni A, Ammendolia MG, Superti F. Bovine lactoferrin: involvement of metal saturation and carbohydrates in the inhibition of influenza virus infection. Biochem Cell Biol. 2012;90(3): 442-448. doi: 10.1139/o11-072.

13. Berlutti F, Pantanella F, Natalizi T, et al. Antiviral properties of lactoferrin — a natural immunity molecule. Molecules. 2011; 16(8):6992-7018. doi: 10.3390/molecules16086992.

14. Ochoa TJ, Sizonenko SV. Lactoferrin and prematurity: a promising milk protein? Biochem Cell Biol. 2016:1-9. doi: 10.1139/bcb-2016-0066.Forthcoming 2016.

15. Buckett WM, Luckas MJ, Gazvani MR, et al. Seminal plasma lactoferrin concentrations in normal and abnormal semen samples. J Androl. 1997;18(3):302-304. doi: 10.1002/j.1939-4640.1997.tb01923.x.

16. Steijns JM, van Hooijdonk AC. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr. 2000;84(Suppl 1):11-17. doi: 10.1017/s0007114500002191.

17. Lonnerdal B. Bioactive proteins in human milk: mechanisms of action. J Pediatr. 2010;156(2 Suppl):26-30. doi: 10.1016/j.jpeds.2009.11.017.

18. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis. 2003;187(1): 87-95. doi: 10.1086/345875.

19. Gomez HF, Ochoa TJ, Herrera-Insua I, et al. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect Immun. 2002;70(12):7050-7053. doi: 10.1128/IAI.70.12.7050-7053.2002.

20. Oda H, Wakabayashi H, Yamauchi K, Abe F. Lactoferrin and bifidobacteria. Biometals. 2014;27(5):915-922. doi: 10.1007/s10534-014-9741-8.

21. Ochoa TJ, Noguera-Obenza M, Ebel F, et al. Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect Immun. 2003;71(9):5149-5155. doi: 10.1128/IAI.71.9.5149-5155.2003.

22. Bruni N, Capucchio MT, Biasibetti E, et al. Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules. 2016;21(6):E752. doi: 10.3390/molecules21060752.

23. Sherman MP, Bennett SH, Hwang FF, Yu C. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals. 2004;17(3):285-289. doi: 10.1023/b:biom.0000027706.51112.62.

24. Valenti P, Visca P, Antonini G, Orsi N. Interaction between lactoferrin and ovotransferrin and Candida cells. FEMS Microbiol Lett. 1986; 33(2-3):271-275. doi: 10.1111/j.1574-6968.1986.tb01285.x.

25. Nikawa H, Samaranayake LP, Tenovuo J, et al. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol. 1996;38(12):1057-1063.

26. Nikawa H, Samaranayake LP, Hamada T. Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch Oral Biol. 1995;40(6):581-584. doi: 10.1016/0003-9969(94)00195-H.

27. Ueno H, Sato T, Yamamoto S, et al. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci. 2006;97(10):1105-1110. doi: 10.1111/j.1349-7006.2006.00274.x.

28. Tsuda H, Sekine K, Fujita K, Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol. 2002;80(1):131-136. doi: 10.1139/o01-239.

29. Rodrigues L, Teixeira J, Schmitt F, et al. Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 2009;49(3):203-217. doi: 10.1080/10408390701856157.

30. Lonnerdal B. Infant formula and infant nutrition: bioactive proteins of human milk and implications for composition of infant formulas. Am J Clin Nutr. 2014;99(3):712-717. doi: 10.3945/ajcn.113.071993.

31. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr. 2010;156(2 Suppl):3-7. doi: 10.1016/j.jpeds.2009.11.021.

32. Global strategy for infant and young child feeding: the optimal duration of exclusive breastfeeding. Geneva: World Health Organization; 2001.

33. Легонькова Т.И., Сенюхина Н.М., Дейнеко О.Я. Питание здоровых детей. — Смоленск: СГМА; 2000. — 67 с. [Legon'kova TI, Senyukhina NM, Deineko OYa. Pitanie zdorovykh detei. Smolensk: SGMA; 2000. 67 p. (In Russ).]

34. Stuebe AM, Schwarz EB. The risks and benefits of infant feeding practices for women and their children. J Perinatol. 2010;30(3): 155-162. doi: 10.1038/jp.2009.107.

35. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000;355(9202):451-455. doi: 10.1016/S0140-6736(00)82011-5.

36. Montagne P, Cuilliere ML, Mole C, et al. Changes in lactoferrin and lysozyme levels in human milk during the first twelve weeks of lactation. Adv Exp Med Biol. 2001;501:241-247. doi: 10.1007/978-1-4615-1371-1_30.

37. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol B. 1971;39(1):119-129.

38. Villavicencio A, Rueda MS, Turin CG, Ochoa TJ. Factors affecting lactoferrin concentration in human milk: how much do we know? Biochem Cell Biol. 2016;4:1-10. doi: 10.1139/bcb-2016-006.

39. Rai D, Adelman AS, Zhuang W, et al. Longitudinal changes in lactoferrin concentrations in human milk: a global systematic review. Crit Rev Food Sci Nutr. 2014;54(12):1539-1547. doi: 10.1080/10408398.2011.642422.

40. Dabrowskal S, Demkow U, Podsiadly E. [Presence of lactoferrin in faeces as the indicator of Clostridium difficile in pediatric patients. (In Polish).] Med Dosw Mikrobiol. 2015;67(1):1-8.

41. Hirai Y, Kawakata N, Satoh K, et al. Concentrations of lactoferrin and iron in human milk at different stages of lactation. J Nutr Sci Vitaminol (Tokyo). 1990;36(6):531-544. doi: 10.3177/ jnsv.36.531.

42. Davidson LA, Lonnerdal B. Persistence of human milk proteins in the breast-fed infant. Acta Paediatr Scand. 1987;76(5):733-740. doi: 10.1111/j.1651-2227.1987.tb10557.x.

43. Muller MJ, Paul T, Seeliger SJ. Necrotizing enterocolitis in premature infants and newborns. Neonatal Perinatal Med. 2016; 9(3):233-242. doi: 10.3233/NPM-16915130.

44. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014;27(1):21-47. doi: 10.1128/CMR.00031-13.

45. PUMHS. Lactoferrin levels in mother's milk. Professional Med J. 2012;19(4):527-530.

46. Cheng JB, Wang JQ, Bu DP, et al. Factors affecting the lactoferrin concentration in bovine milk. J Dairy Sci. 2008;91(3):970-976. doi: 10.3168/jds.2007-0689.

47. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on bovine lactoferrin. EFSA Journal. 2012; 10(5):2701. doi: 10.2903/j.efsa.2012.2701.

48. Velden WJ, van Iersel TM, Blijlevens NM, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med. 2009;7:44. doi: 10.1186/1741-7015-7-44.

49. fda.gov [Internet]. FDA GRAS Notification as GRN 000042. Generally Recognized as Safe Determination for Bovine Lactoferrin. 2001 [cited 2016 Nov 9]. Available from: http://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/Noti-ceInventory/ucm266172.pdf.

50. Патент РФ на изобретение №21-6785. Юки Й., Теразава К., Накагава Т., Кате К. «Способ получения продукта, содержащего активные молочно-белковые компоненты, и продукт, полученный этим способом (варианты)». [Patent RUS №21-6785. Yuki I, Terazava K, Nakagava T, Kate K. «Sposob polucheniya produkta, soderzhashchego aktivnye molochno-belkovye komponenty, i produkt, poluchennyi etim sposobom (varianty)». (In Russ).]

51. Патент РФ на изобретение №2366294. Бюл. №36 от 27.12.2014. Семенов Г.В., Тихомирова Н.А., Комолова Г.С., Овчинникова О.Е. «Способ получения биологически активной добавки «мобелиз» и полученная этим способом БАД «мобелиз»». [Patent RUS №2366294. Byul. №36. Semenov GV, Tikhomirova NA, Komolova GS, Ovchinnikova OE. «Sposob polucheniya biologicheski aktivnoi dobavki «mobeliz» i poluchennaya etim sposobom BAD «mobeliz»». (In Russ).]

52. Manzoni P. Clinical benefits of lactoferrin for infants and children. J Pediatr. 2016;173 Suppl:S43-52. doi: 10.1016/j.jpeds.2016.02.075.

53. urin CG, Zea-Vera A, Pezo A, et al. Lactoferrin for prevention of neonatal sepsis. Biometals. 2014;27(5):1007-1016. doi: 10.1007/s10534-014-9754-3.

54. Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol. 2012; 90(3):233-244. doi: 10.1139/o2012-016.

55. Tomita M, Wakabayashi H, Shin K, et al. Twenty-five years of research on bovine lactoferrin applications. Biochimie. 2009; 91(1):52-57. doi: 10.1016/j.biochi.2008.05.021.

56. King JC Jr, Cummings GE, Guo N, et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J Pediatr Gastroenterol Nutr. 2007;44(2):245-251. doi: 10.1097/01.mpg.0000243435.54958.68.

57. Suzuki YA, Lopez V, Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005;62(22):2560-2575. doi: 10.1007/s00018-005-5371-1.

58. Troost FJ, Steijns J, Saris WH, Brummer RJ. Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr. 2001;131(8):2101-2104.

59. Smith CA, Anderson BF, Baker HM, Baker EN. Metal substitution in transferrins: the crystal structure of human copper-lactoferrin at 2.1-A resolution. Biochemistry. 1992;31(18):4527-4533. doi: 10.1021/bi00133a020.

60. van Veen HA, Geerts ME, van Berkel PH, Nuijens JH. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur J Biochem. 2004; 271(4):678-684. doi: 10.1111/j.1432-1033.2003.03965.x.

61. Якубовская Р.И., Немцова Е.Р, Коханова И.Д., и др. Лакто-феррин человека: получение высокоочищенных препаратов из молока женщин, некоторые физико-химические свойства и распределение в нормальных и опухолевых тканях // Вопросы медицинской химии. — 1986. — Т. 32. — № 6 — С. 75-79. [Yakubovskaya RI, Nemtsova ER, Kokhanova ID, et al. Laktoferrin cheloveka: poluchenie vysokoochishchennykh preparatov iz moloka zhenshchin, nekotorye fiziko-khimicheskie svoistva i raspredelenie v normal'nykh i opukholevykh tkanyakh. Vopr Med Khim. 1986;32(6):75-79. (In Russ).]

62. Патент РФ на изобретение №2165769. Чиссов В.И., Якубовская Р.И., Немцова Е.Р., и др. Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения. [Patent RUS №2165769. Chissov VI, Yakubovskaya RI, Nemtsova ER, et al. Antibakterial'nyi, antioksidantnyi, immunomoduliruyushchii i antikantserogennyi pre-parat i sposob ego primeneniya. (In Russ).] Доступно по: http://ru-patent.info/21/65-69/2165769.html. Ссылка активна на 12.12.2016.

63. Постановление Совета Министров Союзного государства от 21 октября 2014 г. № 28 «Обитогах выполнения научно-технической программы Союзного государства «БелРосТрансген-2 на 20092013 гг.». [Council of Ministers Decision No 28 «Ob itogakh vypolneniya nauchno-tekhnicheskoi programmy Soyuznogo gosudarstva «BelRosTransgen-2 na 2009-2013» dated 2014 Oct 21. (In Russ).]

64. Suzuki YA, Kelleher SL, Yalda D, et al. Expression, characterization, and biologic activity of recombinant human lactoferrin in rice. J Pediatr Gastroenterol Nutr. 2003;36(2):190-199. doi: 10.1097/00005176-200302000-00007.

65. Ward PP, Lo JY, Duke M, et al. Production of biologically active recombinant human lactoferrin in Aspergillus oryzae. Biotechnology (N Y). 1992;10(7):784-789. doi: 10.1038/nbt0792-784.

66. Han ZS, Li QW, Zhang ZY, et al. High-level expression of human lactoferrin in the milk of goats by using replication-defective adenoviral vectors. Protein Expr Purif. 2007;53(1):225-231. doi: 10.1016/j.pep.2006.11.019.

67. van Berkel PH, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transge-nic cows. Nat Biotechnol. 2002;20(5):484-487. doi: 10.1038/nbt0502-484.

68. Goldman IL, Georgieva SG, Gurskiy YG, et al. Production of human lactoferrin in animal milk. Biochem Cell Biol. 2012;90(3):513-519. doi: 10.1139/o11-088.

69. Дейкин А.В., Ермолкевич Т.Г., Гурский Я.Г., и др. Состояние здоровья и воспроизводительная способность трансгенных мышей, продуцирующих с молоком рекомбинантный белок человека лактоферрин // Доклады Академии наук. — 2009. — Т. 427. — №4 — С. 545-548. [Deykin AV, Ermolkevich TG, Gursky YG, et al. The state of health and the reproductive potential of transgenic mice secreting recombinant human lactoferrin in milk. Dokl Akad Nauk. 2009;427(4):545-548. (In Russ).]

70. Гольдман И.Л., Кадулин С.Г., Разин С.В. Трансгенные козы в мировой Фарминдустрии XXI в. // Генетика. — 2002. — Т. 38. — № 1 — С. 5-21. [Goldman IL, Kadulin SG, Razin SV. Transgenic goats in the world pharmaceutical industry of the 21st century. Genetika. 2002;38(1):5-21. (In Russ).]

71. Соколов A.B., Пулина М.О., Кристиян А.В., и др. Исследование рекомбинантного лактоферрина человека, секретируемого в молоко трансгенных мышей // Доклады Академии наук. — 2006. — Т. 411. — № 1 — С. 336-338. [Sokolov AV, Pulina MO, Kristiyan AV, et al. A study of recombinant human lactoferrin secreted in milk of transgenic mice. DoklAkadNauk. 2006;411(1):336-338. (In Russ).]

72. Goldman I, Chernousov A, Sadchikova E. Application potential of recombinant human lactoferrin in antibiotic-resistant infection control. In: Anninos P, Rossi M, Pham TD, et al, editors. Resent advances in clinical medicine. Cambridge: WSEAS Press; 2010. p. 315-321.

73. Черноусов А.Д., Никонова М.Ф., Шарова Н.И., и др. Неолактоферрин как стимулятор врожденного и адаптивного иммунитета // Acta Naturae. — 2013. — Т. 5. — № 4 — С. 67-73. [Chernousov AD, Nikonova MF, Sharova NI, et al. Neolactoferrin as a stimulator of innate and adaptive immunity. Acta Naturae. 2013;5(4):67-73. (In Russ).]